Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer

NCT06145750 is registered in ClinicalTrials.gov with Delfi Diagnostics Inc. as lead sponsor.

NCT NCT06145750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06145750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
Lead sponsor
Delfi Diagnostics Inc.
Phase
Not applicable
Overall status
Completed
Start date
October 31, 2023
Completion date
August 31, 2025
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer